South African pharmaceutical company Aspen has secured regulatory approval to market Mounjaro for chronic weight management, positioning the local manufacturer to compete in the rapidly expanding global market for weight-loss medications.
The approval from the South African Health Products Regulatory Authority SAHPRA clears the way for the once-weekly injection to become available to patients starting October.
The development represents a significant expansion of treatment options for weight management in South Africa, where obesity affects a growing portion of the population.